Zura Bio rises on positive early-stage results for immune disease drug

Zura Bio

14/06/2024 12:50

** Shares of biotech co Zura Bio  ZURA.O  rise 4.7% to $3.90
premarket 
    ** Co says its lead experimental drug tibulizumab was well
tolerated in a early-stage study testing it in patients with
Sjogren's syndrome 
    ** Sjogren's syndrome is an autoimmune disease that is
caused when the immune system damages the glands that produce
and control moisture in body
     ** Co says the drug helped in neutralizing the inflammatory
response of IL-17A and BAFF proteins that play a role in various
immune diseases 
    ** Up to last close, stock has fallen 20.1% YTD 

 (Reporting by Sneha S K in Bengaluru)
 ((Sneha.SK@thomsonreuters.com;))